Obesity diminishes response to immunotherapy in kidney cancer

In this study, the researchers looked at the interaction between obesity and outcomes in patients taking immune checkpoint inhibitors (anti-PD-1 immunotherapy, e.g. nivolumab, pembrolizumab) for the treatment of renal cell carcinoma (RCC). Seventy-two (72) patients with metastatic RCC were treated with anti–PD-1 immunotherapy (none had been treated with immunotherapy before). Obese patients had poorer progression-free […]

read more

Individualising first line treatment for advanced kidney cancer

In recent years, a number of new, effective treatments have become available for advanced kidney cancer. However, with more drugs available it has become more difficult to decide which drugs to choose for particular patients, and in which order to use them. In addition, the new treatments do not work for all patients and they […]

read more

Liquid biopsies in kidney cancer

In this review, the key substances found in the blood, such as circulating free (cf)DNA, cfRNA, proteins, and exosomes (sacs containing proteins, DNA and/or RNA), which may act as biomarkers for monitoring the progression of clear cell renal cell carcinoma (ccRCC) are discussed. Limitations of these techniques and promising technologies that could help with the […]

read more

Outcomes of complete metastasectomy in metastastic kidney cancer

A recent study from Canada investigated the use of surgery to remove metastases (metastasectomy)  as part of the treatment of metastatic renal cell carcinoma (RCC) and whether this delayed progression of the disease and improved survival. Real world data from 229 Canadian patients was used in this study. These data were matched with 803 control […]

read more

Patterns of initial metastatic recurrence after surgery for high-risk kidney cancer patients

This study looked at where metastases occurred after surgery for high-risk non-metastatic renal cell carcinoma (RCC). The study also identified the factors that indicated outcomes for these patients. A total of 1,057 patients with stage T3a or greater RCC were treated with surgery. 160 patients (59.3%) had one site of initial metastatic recurrence, while 110 […]

read more

Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer

KCSN are formal consultants to NICE and part of the process that appraises all new kidney cancer drugs. We are delighted to tell you that, as from today, kidney cancer patients can get NHS funding via the Cancer Drugs Fund for avelumab in combination with axitinib as a first-line treatment for patients with untreated advanced […]

read more

Combination of potential biomarkers may help predict response to immunotherapy in kidney cancer

Currently, it is difficult for clinicians to decide which patients will respond to immunotherapy and, therefore, what is the best course of treatment for patients with metastatic renal cell carcinoma (RCC). A recent study published in Oncoimmunology describes a combination of two potential biomarkers that may help predict response to immunotherapy for metastatic RCC patients, […]

read more

Summary from ASCO 2020 virtual meeting

This article nicely summarises the most exciting research highlights from the ASCO 2020 Virtual Scientific Programme which demonstrate the evolution of treatments for advanced renal cell carcinoma (RCC), with a focus on combination treatments, salvage therapies and treatments for non-clear cell RCC. Read the review article in the Journal of Clinical Oncology here

read more

Re-treatment with immune checkpoint inhibitors in kidney cancer patients

Immune checkpoint inhibitor combinations for the treatment of patients with metastatic renal cell carcinoma (RCC) have shown considerable promise. However, disease progression is inevitable for most patients. A recent review article published in Nature Reviews Clinical Oncology summarises the results of re-treatment with immune checkpoint inhibitors. Two retrospective studies investigated the safety and efficacy of […]

read more

Potential biomarker to predict outcomes in metastatic kidney cancer

A recent study published in Targeted Oncology last month investigates the role of an enzyme called γ-glutamyltransferase (GGT) as a potential biomarker for metastatic renal cell carcinoma (RCC). High levels of GGT in the blood has been linked with poor survival in various cancers; however, there are no data for metastatic RCC patients. This study […]

read more
Showing 1 to 10 of 41 results
  TOP